Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (267)	2/11/1999 12:52:00 AM
From: Vector1	Respond to of 804

<<I am sick of this BS, so please let leave ENMD to ENMD tread. This tread is about >> Well said Miljenko. I couldn't agree more. V1

To: Miljenko Zuanic who wrote (267)	2/11/1999 8:51:00 AM
From: LLCF	Read Replies (1) \| Respond to of 804

<I am sick of this BS, so please let leave ENMD to ENMD tread. This tread is about CELG.> I agree, I'm here to learn about CELG not talk about ENMD, however I am also here to talk about anything to do with the deals pharma's including CELG might make. I stated in my post that I was talking about rights of refusal vs options (to take a product back inhouse for example), an important distinction IMO and not BS. I further stated I could not comment on weather Bristol had an interest in the "product" or not. I will state further that having a ROR (right of refusal) does NOT preclude that party from appoaching the owner themselves to purchase that asset or the owner from "shopping" the product. Sorry for "glocking" up the thread, last post on it here on the subject unless it comes up in relation to CELG. DAK